ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Equities
1541
CNE100006624
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.64 HKD | +2.66% | +0.55% | -51.04% |
06-03 | ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug | MT |
05-30 | ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.04% | 682M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- 1541 Stock
- News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases